Payment overview · 2025
General Payments
$431.31
23 reported records · 10 companies
Healthcare provider profile · identity verified
Kully Lynn Woodruff, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NEW BERN, NC · NPI 1750624813
Verified facts
What the public records show
CMS Open Payments records show Kully Lynn Woodruff, M.D. received $431.31 in general payments during 2025 across 23 reported records.
GlaxoSmithKline, LLC. accounted for 24.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $104.05 | 24.1% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $82.20 | 19.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.40 | 17.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $73.50 | 17.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.61 | 5.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.93 | 3.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $14.92 | 3.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.69 | 3.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.51 | 3.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.50 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $431.31 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $104.05 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $82.20 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.95 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $54.95 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $25.61 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $14.92 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 97 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
52 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
25 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
97 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 555 | 149 |
| Amlodipine Besylate | Amlodipine Besylate | 323 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 314 | 81 |
| Losartan Potassium | Losartan Potassium | 306 | 80 |
| Omeprazole | Omeprazole | 270 | 70 |
| Metformin Hcl Er | Metformin Hcl | 216 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 211 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 185 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 183 | 49 |
| Montelukast Sodium | Montelukast Sodium | 183 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 44 |
| Potassium Chloride | Potassium Chloride | 154 | 44 |
| Lisinopril | Lisinopril | 148 | 41 |
| Gabapentin | Gabapentin | 135 | 29 |
| Famotidine | Famotidine | 130 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 120 | 25 |
| Alendronate Sodium | Alendronate Sodium | 116 | 40 |
| Fluoxetine Hcl | Fluoxetine Hcl | 111 | 22 |
| Eliquis | Apixaban | 108 | 21 |
| Prednisone | Prednisone | 104 | 72 |
| Ozempic | Semaglutide | 97 | 24 |
| Meloxicam | Meloxicam | 85 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 85 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 83 | 53 |
| Trazodone Hcl | Trazodone Hcl | 82 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 79 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 22 |
| Furosemide | Furosemide | 77 | 30 |
| Sertraline Hcl | Sertraline Hcl | 77 | 22 |
| Lorazepam | Lorazepam | 76 | 23 |
| Carvedilol | Carvedilol | 71 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 71 | 16 |
| Tramadol Hcl | Tramadol Hcl | 71 | 19 |
| Metformin Hcl | Metformin Hcl | 69 | 16 |
| Simvastatin | Simvastatin | 66 | 15 |
| Spironolactone | Spironolactone | 65 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 26 |
| Jardiance | Empagliflozin | 60 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 59 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 14 |
| Celecoxib | Celecoxib | 56 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 14 |
| Bupropion Xl | Bupropion Hcl | 52 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 52 | 14 |
| Valsartan | Valsartan | 52 | suppressed |
| Allopurinol | Allopurinol | 48 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 47 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 47 | suppressed |
| Alprazolam | Alprazolam | 45 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 12 |
| Telmisartan | Telmisartan | 41 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 22 |
| Ventolin Hfa | Albuterol Sulfate | 36 | 14 |
| Azithromycin | Azithromycin | 35 | 30 |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 30 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | 14 |
| Pregabalin | Pregabalin | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 19 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 25 | 24 |
| Diazepam | Diazepam | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 23 | suppressed |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 14 |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Nystatin | Nystatin | 20 | 12 |
| Primidone | Primidone | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 14 |
| Cephalexin | Cephalexin | 19 | 14 |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $431.31 · 23 records | GlaxoSmithKline, LLC. | Auvelity, BREZTRI, Dexcom G6 Transmitter, FREESTYLE LIBRE 2, MOUNJARO, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, Wegovy, YUPELRI, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error